Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 63629-8483

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63629-8483). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (30406488 Figure 01)

Chemical structure of Donepezil Hydrochloride showing the molecular arrangement including aromatic rings, methoxy groups, and a piperidine ring linked to the hydrochloride ion.*

FDA Label Image

Figure2 (30406488 Figure 02)

Line graph depicting ADAS-cog mean change from baseline over weeks of drug treatment for Donepezil Hydrochloride tablets at 10 mg/day and 5 mg/day doses compared to placebo. The vertical axis shows clinical improvement and decline, and the horizontal axis shows treatment duration up to 24 weeks, with an additional placebo observation at 30 weeks. Error bars indicate standard error.*

FDA Label Image

Figure-03 (30406488 Figure 03)

A cumulative percentage of patients graph showing change from baseline on the x-axis and cumulative percentage on the y-axis. It compares Placebo, Donepezil Hydrochloride Tablets 5 mg/day, and 10 mg/day groups, illustrating their effects on patient outcomes with annotations at 7 points, 4 points, and no change, alongside a small table summarizing treatment group percentages for different change levels in ADAS-cog scores.*

FDA Label Image

Figure-04 (30406488 Figure 04)

Bar graph showing the distribution of CIBIC-plus ratings among patients taking Donepezil Hydrochloride Tablets at 10 mg/day, 5 mg/day, and placebo. The x-axis categorizes ratings from markedly improved to markedly worse, while the y-axis shows the percentage of patients. The chart compares efficacy and patient response across the three groups.*

FDA Label Image

Figure-05 (30406488 Figure 05)

A line chart showing the change from baseline in ADAS-cog scores over 12 weeks of treatment, comparing Donepezil Hydrochloride Tablets at 10 mg/day, 5 mg/day, and placebo. The y-axis represents mean change (±SE) from baseline, with clinical improvement below and clinical decline above zero. The x-axis shows weeks of treatment with a marked placebo period after week 12.*

FDA Label Image

Figure-06 (30406488 Figure 06)

A cumulative percentage of patients plot showing changes from baseline in ADAS-cog scores for treatment groups: Placebo, Donepezil Hydrochloride Tablets 5 mg/day, and 10 mg/day. The x-axis represents change from baseline, while the y-axis shows cumulative patient percentage. The graph includes reference lines at 7 points, 4 points, and no change, with a table summarizing percentage of patients achieving specified score changes in each group.*

FDA Label Image

Figure-07 (30406488 Figure 07)

Bar chart depicting the percentage of patients across different categories of clinical response (Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, Markedly Worse) for three groups: Donepezil Hydrochloride Tablets 10 mg/day, Donepezil Hydrochloride Tablets 5 mg/day, and Placebo. The chart compares patient outcomes based on treatment dosage versus placebo.*

FDA Label Image

08 (30406488 Figure 08)

A line graph illustrating the SIB change from baseline mean (±SE) over 6 months of drug treatment. It compares Donepezil Hydrochloride Tablets 10 mg/day (solid circles) showing clinical improvement to placebo (open squares) indicating clinical decline. The x-axis represents months of drug treatment (0, 3, 6), and the y-axis shows SIB change ranging from -8 to 8 with labels for clinical improvement, baseline, and clinical decline.*

FDA Label Image

09 (30406488 Figure 09)

A cumulative percentage graph comparing patients treated with Donepezil Hydrochloride Tablets 10 mg/day versus placebo. The x-axis shows SIB (Severe Impairment Battery) change from baseline, and the y-axis shows the cumulative percentage of patients, illustrating treatment effect differences between Donepezil and placebo groups.*

FDA Label Image

10 (30406488 Figure 10)

A line graph showing ADCS-ADL change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride Tablets 10 mg/day and placebo. The y-axis represents mean change with standard error, indicating clinical improvement or decline, while the x-axis represents months of treatment. Donepezil shows less clinical decline compared to placebo.*

FDA Label Image

11 (30406488 Figure 11)

A cumulative percentage plot showing patient response comparing Donepezil Hydrochloride 10 mg/day tablets versus placebo. The horizontal axis represents ADCS-ADL change from baseline with values decreasing leftwards, and the vertical axis shows the cumulative percentage of patients from 0 to 100%. Two lines indicate the cumulative distribution for Donepezil (solid circles) and placebo (open squares).*

FDA Label Image

12 (30406488 Figure 12)

A line graph showing SIB (Severe Impairment Battery) change from baseline (least squares mean ± SE) over 24 weeks of drug treatment. Two lines represent Donepezil Hydrochloride Tablets at 23 mg/day and 10 mg/day doses. The 23 mg/day line shows a greater clinical improvement over time compared to the 10 mg/day dose, which remains near baseline with less improvement.*

FDA Label Image

13 (30406488 Figure 13)

Cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline comparing Donepezil Hydrochloride Tablets 23 mg/day and 10 mg/day doses. The horizontal axis represents SIB change from baseline, and the vertical axis shows cumulative percentage of patients. Two data series are illustrated with different markers for the two dosages.*

FDA Label Image

14 (30406488 Figure 14)

A bar graph comparing the percentage of patients with different CIBIC-plus ratings for Donepezil Hydrochloride Tablets at 23 mg/day and 10 mg/day. The ratings range from Markedly Improved to Markedly Worse, showing patient response distribution across both dosages.*

FDA Label Image

15 (30406488 Figure 15)

FDA Label Image

Label (Lbl636298483)

Donepezil Hydrochloride 23 mg film-coated tablets label from Bryant Ranch Prepack. The label shows the NDC 63629-8483-1, the dosage strength of 23 mg, and indicates 30 tablets per container. It includes storage instructions at 20° to 25°C and a caution not to accept if the bottle seal is broken or missing. The label also displays a barcode and the BRP Pharmaceuticals logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.